JP2010524971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524971A5 JP2010524971A5 JP2010504279A JP2010504279A JP2010524971A5 JP 2010524971 A5 JP2010524971 A5 JP 2010524971A5 JP 2010504279 A JP2010504279 A JP 2010504279A JP 2010504279 A JP2010504279 A JP 2010504279A JP 2010524971 A5 JP2010524971 A5 JP 2010524971A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- pharmaceutical composition
- composition according
- antitrypsin
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 27
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 27
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 102000012479 Serine Proteases Human genes 0.000 claims description 16
- 108010022999 Serine Proteases Proteins 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 206010038997 Retroviral infections Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 208000022338 anthrax infection Diseases 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 229940125687 antiparasitic agent Drugs 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 230000002584 immunomodulator Effects 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 2
- 208000010334 End Stage Liver Disease Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010058838 Enterocolitis infectious Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims description 2
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 2
- 206010030216 Oesophagitis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 231100000836 acute liver failure Toxicity 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 230000002223 anti-pathogen Effects 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims description 2
- 201000009904 bacterial meningitis Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 208000011444 chronic liver failure Diseases 0.000 claims description 2
- 238000002651 drug therapy Methods 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000006881 esophagitis Diseases 0.000 claims description 2
- 206010017931 gastrointestinal anthrax Diseases 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 208000027139 infectious colitis Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 201000008222 ischemic colitis Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 2
- 239000003001 serine protease inhibitor Substances 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 101710081722 Antitrypsin Proteins 0.000 claims 1
- 230000001475 anti-trypsic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- RDFCSSHDJSZMTQ-ZDUSSCGKSA-N Tos-Lys-CH2Cl Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 RDFCSSHDJSZMTQ-ZDUSSCGKSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- HVXFLNJFYRWDQU-UHFFFAOYSA-N 3-[4-[2-[4-[1-[4-(2-carboxy-2-methylpropyl)sulfonylphenoxy]-2-methyl-1-oxopropan-2-yl]phenyl]-2-methylpropanoyl]oxyphenyl]sulfonyl-2,2-dimethylpropanoic acid Chemical compound C1=CC(S(=O)(=O)CC(C)(C)C(O)=O)=CC=C1OC(=O)C(C)(C)C1=CC=C(C(C)(C)C(=O)OC=2C=CC(=CC=2)S(=O)(=O)CC(C)(C)C(O)=O)C=C1 HVXFLNJFYRWDQU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- FPGAGACTKJTPFT-MYKRZTLLSA-N benzyl n-[(2s)-3-methyl-1-[(2s)-2-[[(2s)-3-methyl-1-[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)C=1OC(CC=2C=C(C)C=CC=2)=NN=1)C(=O)OCC1=CC=CC=C1 FPGAGACTKJTPFT-MYKRZTLLSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000004867 thiadiazoles Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91317407P | 2007-04-20 | 2007-04-20 | |
| PCT/US2008/060848 WO2009005877A2 (en) | 2007-04-20 | 2008-04-18 | Alpha-i antitrypsin having no significant serine protease inhibitor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524971A JP2010524971A (ja) | 2010-07-22 |
| JP2010524971A5 true JP2010524971A5 (OSRAM) | 2011-06-02 |
Family
ID=39872858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504279A Withdrawn JP2010524971A (ja) | 2007-04-20 | 2008-04-18 | 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080261869A1 (OSRAM) |
| EP (1) | EP2148693A4 (OSRAM) |
| JP (1) | JP2010524971A (OSRAM) |
| AU (1) | AU2008270951A1 (OSRAM) |
| CA (1) | CA2722015A1 (OSRAM) |
| WO (1) | WO2009005877A2 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000051624A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Methods and compositions useful in inhibiting apoptosis |
| US6849605B1 (en) | 1999-03-05 | 2005-02-01 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| US20100210528A1 (en) * | 1999-03-05 | 2010-08-19 | Leland Shapiro | Compositions, methods and uses for inhibition and/or treatment of influenza infection |
| WO2000051625A1 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses |
| US20100144630A1 (en) * | 1999-03-05 | 2010-06-10 | Leland Shapiro | Compositions, methods and uses for inhibition and/or treatment of influenza infection |
| JP2007504144A (ja) * | 2003-08-26 | 2007-03-01 | ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト | セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法 |
| US8715649B2 (en) * | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| WO2012012146A2 (en) * | 2010-06-30 | 2012-01-26 | The Regents Of The University Of Colorado | Compositions and methods to modulate progression and onset of inflammatory bowel disease |
| FR2970417A1 (fr) * | 2011-01-19 | 2012-07-20 | Lfb Biotechnologies | Association de proteine c et d'alpha1-antitrypsine pour le traitement du sepsis ou du choc septique |
| US9938353B2 (en) * | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| KR20140137347A (ko) | 2012-01-10 | 2014-12-02 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
| US9422336B2 (en) | 2012-05-25 | 2016-08-23 | Well Resources Limited | Peptide for treatment of disease or symptoms associated with pain |
| US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| WO2014160768A1 (en) * | 2013-03-29 | 2014-10-02 | The Regents Of The University Of Colorado | Compositions and methods for preparing a subject for organ or non-organ implantation |
| CN105431165A (zh) * | 2013-05-15 | 2016-03-23 | 莫尔研究应用有限公司 | 用于治疗心肺手术后的术后并发症的组合物和方法 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| CN112315897A (zh) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法 |
| EP4240323A1 (en) * | 2020-11-06 | 2023-09-13 | AATEC Medical GmbH | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
| WO2024261179A1 (en) * | 2023-06-22 | 2024-12-26 | Aatec Medical Gmbh | Recombinant aat from yeast to treat bacterial respiratory infections |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604201A (en) * | 1993-01-08 | 1997-02-18 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | Methods and reagents for inhibiting furin endoprotease |
-
2008
- 2008-04-18 EP EP08826069A patent/EP2148693A4/en not_active Withdrawn
- 2008-04-18 JP JP2010504279A patent/JP2010524971A/ja not_active Withdrawn
- 2008-04-18 WO PCT/US2008/060848 patent/WO2009005877A2/en not_active Ceased
- 2008-04-18 US US12/106,052 patent/US20080261869A1/en not_active Abandoned
- 2008-04-18 CA CA2722015A patent/CA2722015A1/en not_active Abandoned
- 2008-04-18 AU AU2008270951A patent/AU2008270951A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524971A5 (OSRAM) | ||
| WO2023155318A1 (zh) | 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用 | |
| JP2010524971A (ja) | 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン | |
| JP2012115277A5 (OSRAM) | ||
| EP2288615B1 (en) | Selective caspase inhibitors and uses thereof | |
| CA2996975C (en) | Methods for treatment of diseases | |
| AU2013270682A1 (en) | Procoagulant compounds | |
| JP2005516885A5 (OSRAM) | ||
| JP2008536483A5 (OSRAM) | ||
| JP2007535910A5 (OSRAM) | ||
| ES2343732T3 (es) | Interferon beta para la terapia antivirica de enfermedades respiratorias. | |
| Schneider et al. | Development of HIV fusion inhibitors | |
| JP2017537888A5 (OSRAM) | ||
| JP2017521074A5 (OSRAM) | ||
| CN101372512B (zh) | 一类抗凝血多肽及其用途 | |
| US7314858B2 (en) | Retrocyclins: antiviral and antimicrobial peptides | |
| WO2021198395A1 (en) | Surfactant protein d for use in treating coronavirus infections | |
| Nishikawa et al. | Identification of minimal sequence for HIV-1 fusion inhibitors | |
| JP2007536910A5 (OSRAM) | ||
| US9045524B2 (en) | Selective caspase inhibitors and uses thereof | |
| JP2010511706A5 (OSRAM) | ||
| JP2011501675A5 (OSRAM) | ||
| CN104311644B (zh) | 多肽、提高多肽稳定性的方法、药物组合物以及多肽在制备药物中的用途 | |
| JP2007326781A (ja) | 抗ｓａｒｓウイルス剤 | |
| PT99791B (pt) | Processo para a preparacao de peptidos seleccionados do antigene especifico de grupo (gas) do virus da imunodeficiencia humana (hiv) e de composicoes farmaceu-ticas que os contem |